Bioventus Inc. provided earnings guidance for the fourth quarter and full-year ending December 31, 2021. For the quarter, the company's Preliminary, unaudited revenue expected to be in the range of $128.5 to $131.5 million, reflecting 30% to 33% growth compared to the prior-year period.

For the full-year, the company's Preliminary, unaudited revenue expected to be in the range of $429 to $432 million, reflecting an increase of approximately 34% compared to full-year 2020.